Solara Active Pharma Sciences' Q3 FY 2025-26 Quarterly Results
- 07 Feb 2026
Result Summary
- Solara Active Pharma Sciences Ltd reported a 11.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.6%.
- Its expenses for the quarter were up by 11.0% QoQ and 22.5% YoY.
- The net profit increased 72.6% QoQ and decreased 315.5% YoY.
- The earnings per share (EPS) of Solara Active Pharma Sciences Ltd declined at 3.98 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 349.00 | 314.03 | 301.80 | 11.1% | 15.6% |
Total Expenses | 359.68 | 324.13 | 293.71 | 11.0% | 22.5% |
Profit Before Tax | -17.43 | -10.10 | 8.09 | 72.6% | -315.5% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -17.43 | -10.10 | 8.09 | 72.6% | -315.5% |
Earnings Per Share | -3.98 | -2.36 | 2.03 | 68.6% | -296.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Solara Active Pharma Sciences Ltd is a company involved in the pharmaceutical industry, focusing primarily on the development and manufacture of active pharmaceutical ingredients (APIs). The company is known for its expertise in the production of key APIs and intermediates, which are essential components used by pharmaceutical companies in drug formulation. Solara operates in a competitive industry characterized by innovation and stringent regulatory standards. However, specific recent major developments or strategic initiatives undertaken by Solara Active Pharma Sciences Ltd are not available in the provided data.
Revenue
During Q3FY26, Solara Active Pharma Sciences Ltd reported a total income of ₹349.00 crores, marking an increase from ₹314.03 crores in Q2FY26, which translates to a quarter-over-quarter (QoQ) growth of 11.1%. Compared to the same quarter in the previous fiscal year, Q3FY25, where the total income was ₹301.80 crores, there is a year-over-year (YoY) increase of 15.6%. This growth in revenue suggests an upward trend in the company's income generation over both the quarterly and annual periods.
Profitability
The financial report for Solara Active Pharma Sciences Ltd in Q3FY26 indicates that the company experienced a loss, with a Profit Before Tax (PBT) of -₹17.43 crores, compared to -₹10.10 crores in Q2FY26, resulting in a 72.6% increase in the loss QoQ. When compared to Q3FY25, when the company had a PBT of ₹8.09 crores, there is a significant negative YoY change of -315.5%. Consequently, the Profit After Tax (PAT) mirrors these figures, as no tax was applied, resulting in identical figures for PBT and PAT. The Earnings Per Share (EPS) also reflected this trend, showing a negative value of -₹3.98 in Q3FY26, down from -₹2.36 in Q2FY26, and a significant drop from ₹2.03 in Q3FY25.
Operating Metrics
The total expenses for Solara Active Pharma Sciences Ltd in Q3FY26 were ₹359.68 crores, which shows an increase from ₹324.13 crores in Q2FY26, representing a QoQ rise of 11.0%. Compared to Q3FY25's expenses of ₹293.71 crores, there is a YoY increase of 22.5%. This indicates a trend of rising operational costs over both the quarterly and annual timelines. The absence of any tax liability in the financial data suggests no tax was due or deferred in the reported quarter. The EPS figures, being negative in the recent quarter, illustrate the impact of the current financial performance on shareholder returns.